Edwards Life Sciences Corp. (EW): Today's Featured Health Services Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Edwards Life ( EW) pushed the Health Services industry lower today making it today's featured Health Services laggard. The industry as a whole closed the day down 0.4%. By the end of trading, Edwards Life fell $1.15 (-1.3%) to $90.59 on average volume. Throughout the day, 941,978 shares of Edwards Life exchanged hands as compared to its average daily volume of 1.2 million shares. The stock ranged in price between $90.39-$92.55 after having opened the day at $91.95 as compared to the previous trading day's close of $91.74. Other companies within the Health Services industry that declined today were: USMD Holdings ( USMD), down 12.7%, IsoRay ( ISR), down 11.5%, Urologix ( ULGX), down 9.1%, and EnteroMedics ( ETRM), down 7.9%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases or critically ill patients worldwide. Edwards Life has a market cap of $10.63 billion and is part of the health care sector. The company has a P/E ratio of 40.4, above the S&P 500 P/E ratio of 17.7. Shares are up 30.2% year to date as of the close of trading on Tuesday. Currently there are nine analysts that rate Edwards Life a buy, two analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates Edwards Life as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, Harvard Bioscience ( HBIO), up 12.9%, Dynatronics Corporation ( DYNT), up 9.7%, Kips Bay Medical ( KIPS), up 7.2%, and Misonix ( MSON), up 7%, were all gainers within the health services industry with Laboratory Corporation of America Holdings ( LH) being today's featured health services industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Edwards Lifesciences: Cramer's Top Takeaways

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Hold on Concert's Hair Loss Trials Pushes Shares Down 10%

Edwards Lifesciences Is Not Skipping A Beat

Canaccord Says Edwards Lifesciences Is Its Favorite Med Tech Stock